Ann: Cynata announces CEO succession and Board changes, page-79

See the non-holders on here still love digging despite Sector's absence, with banal comments nothing to do with the the thread.

$20 million a lot of money for CYP? Ha, ha. How did you feel about Fate Therapeutics at $6 billion US mkt cap? How did you feel when Sumitomo offered $200 milion for CYP and its trials less advanced? Perhaps you should short it as many brave investors did MSB for nice profit in 2020?

MSB is trading over $1 billion AUD. Its still cheap given its potential in so many investors opinion on Hot Copper (and mine). Whist CYP is far behind MSB in many respects, its absurdly cheap at $23 million with the largest phase III IPSC trial globally in motion and funded by the Australian Government National Health and Medical. Research Council (NHMRC).

I am sure the markets view on the prospects of CYP will quickly change once they get some credible commentary on CYP's Sculptor and other trials' and commercialisation pathway progress, which the past CEO failed to adequately do. BioScience Managers' influence, after all an international healthcare investment firm, will likely see better communication to capital mkts at the very least.